Logo image of MYNZ

MAINZ BIOMED NV (MYNZ) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MYNZ - NL0015000LC2 - Common Stock

1.17 USD
-0.01 (-0.85%)
Last: 1/12/2026, 6:49:00 PM
1.1701 USD
+0 (+0.01%)
After Hours: 1/12/2026, 6:49:00 PM
Fundamental Rating

2

Overall MYNZ gets a fundamental rating of 2 out of 10. We evaluated MYNZ against 528 industry peers in the Biotechnology industry. Both the profitability and financial health of MYNZ have multiple concerns. MYNZ is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MYNZ has reported negative net income.
MYNZ had a negative operating cash flow in the past year.
In the past 5 years MYNZ always reported negative net income.
MYNZ had a negative operating cash flow in each of the past 5 years.
MYNZ Yearly Net Income VS EBIT VS OCF VS FCFMYNZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

MYNZ's Return On Assets of -220.85% is on the low side compared to the rest of the industry. MYNZ is outperformed by 89.20% of its industry peers.
MYNZ has a worse Return On Equity (-858.34%) than 78.03% of its industry peers.
Industry RankSector Rank
ROA -220.85%
ROE -858.34%
ROIC N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYNZ Yearly ROA, ROE, ROICMYNZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

With a decent Gross Margin value of 64.31%, MYNZ is doing good in the industry, outperforming 79.92% of the companies in the same industry.
MYNZ's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for MYNZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
MYNZ Yearly Profit, Operating, Gross MarginsMYNZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYNZ has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MYNZ has been increased compared to 5 years ago.
Compared to 1 year ago, MYNZ has an improved debt to assets ratio.
MYNZ Yearly Shares OutstandingMYNZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
MYNZ Yearly Total Debt VS Total AssetsMYNZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -16.20, we must say that MYNZ is in the distress zone and has some risk of bankruptcy.
MYNZ has a Altman-Z score of -16.20. This is amonst the worse of the industry: MYNZ underperforms 80.11% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that MYNZ is not too dependend on debt financing.
MYNZ has a worse Debt to Equity ratio (0.44) than 69.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -16.2
ROIC/WACCN/A
WACC6.19%
MYNZ Yearly LT Debt VS Equity VS FCFMYNZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.52 indicates that MYNZ may have some problems paying its short term obligations.
MYNZ has a Current ratio of 0.52. This is amonst the worse of the industry: MYNZ underperforms 90.15% of its industry peers.
MYNZ has a Quick Ratio of 0.52. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.43, MYNZ is doing worse than 90.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.43
MYNZ Yearly Current Assets VS Current LiabilitesMYNZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

6

3. Growth

3.1 Past

MYNZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.47%, which is quite impressive.
MYNZ shows a decrease in Revenue. In the last year, the revenue decreased by -0.17%.
The Revenue has been growing by 26.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.55%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%-44.95%

3.2 Future

MYNZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.04% yearly.
MYNZ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 133.71% yearly.
EPS Next Y83.39%
EPS Next 2Y38.62%
EPS Next 3Y24.17%
EPS Next 5Y15.04%
Revenue Next Year-17.68%
Revenue Next 2Y-7.02%
Revenue Next 3Y32.9%
Revenue Next 5Y133.71%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MYNZ Yearly Revenue VS EstimatesMYNZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
MYNZ Yearly EPS VS EstimatesMYNZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MYNZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MYNZ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYNZ Price Earnings VS Forward Price EarningsMYNZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYNZ Per share dataMYNZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as MYNZ's earnings are expected to grow with 24.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y24.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYNZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MAINZ BIOMED NV

NASDAQ:MYNZ (1/12/2026, 6:49:00 PM)

After market: 1.1701 +0 (+0.01%)

1.17

-0.01 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-26 2025-09-26
Earnings (Next)03-30 2026-03-30/amc
Inst Owners5.62%
Inst Owner ChangeN/A
Ins Owners0.84%
Ins Owner ChangeN/A
Market Cap10.04M
Revenue(TTM)894.00K
Net Income(TTM)-21.65M
Analysts82.86
Price Target14.28 (1120.51%)
Short Float %2.5%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)26.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.23
P/FCF N/A
P/OCF N/A
P/B 3.98
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.36
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0.1
BVpS0.29
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -220.85%
ROE -858.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.31%
FCFM N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.98%
Cap/Sales 31.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.43
Altman-Z -16.2
F-Score5
WACC6.19%
ROIC/WACCN/A
Cap/Depr(3y)139.31%
Cap/Depr(5y)92.63%
Cap/Sales(3y)121.7%
Cap/Sales(5y)74.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.55%
EPS Next Y83.39%
EPS Next 2Y38.62%
EPS Next 3Y24.17%
EPS Next 5Y15.04%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%-44.95%
Revenue Next Year-17.68%
Revenue Next 2Y-7.02%
Revenue Next 3Y32.9%
Revenue Next 5Y133.71%
EBIT growth 1Y30.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.02%
OCF growth 3YN/A
OCF growth 5YN/A

MAINZ BIOMED NV / MYNZ FAQ

What is the fundamental rating for MYNZ stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYNZ.


What is the valuation status of MAINZ BIOMED NV (MYNZ) stock?

ChartMill assigns a valuation rating of 1 / 10 to MAINZ BIOMED NV (MYNZ). This can be considered as Overvalued.


Can you provide the profitability details for MAINZ BIOMED NV?

MAINZ BIOMED NV (MYNZ) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for MYNZ stock?

The Earnings per Share (EPS) of MAINZ BIOMED NV (MYNZ) is expected to grow by 83.39% in the next year.